Discover
DOC Updates
DOC Updates
Author: American Diabetes Association
Subscribed: 1,473Played: 34,602Subscribe
Share
© American Diabetes Association
Description
DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles in the field of diabetes research and care, including the American Diabetes Association's three science and health journals – Diabetes, Diabetes Care, and Diabetes, Obesity, and Cardiometabolic CARE. Each episode is approximately 15 minutes long and presents 5-6 recently published articles from ADA journals and beyond.
Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research and information published in journals of the American Diabetes Association and beyond are relevant to clinical practice and can be applied in a treatment setting.
For more information about each of ADA's science and medical journals, please visit www.diabetesjournals.org.
Presented by:
Neil Skolnik, M.D. , Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
John J. Russell, M.D., Clinical Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health
Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research and information published in journals of the American Diabetes Association and beyond are relevant to clinical practice and can be applied in a treatment setting.
For more information about each of ADA's science and medical journals, please visit www.diabetesjournals.org.
Presented by:
Neil Skolnik, M.D. , Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
John J. Russell, M.D., Clinical Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health
322 Episodes
Reverse
Once thought to be rare, an emerging understanding shows that hypercortisolism plays a significant role in both diabetes and hypertension. In this special episode of DOC Updates, Neil Skolnik explores the downstream consequences of undiagnosed hypercortisolism and how to make an effective diagnosis. This special episode is sponsored with support from Corcept. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Pamela Kushner, MD, Clinical Professor of Family Medicine at the University of California at Irvine and Medical Director of the Kushner Wellness Center in Los Angeles. Vivian Fonseca, MD, Professor of Medicine and Pharmacology Assistant Dean for Clinical Research Tullis Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Health Sciences Selected References: Buse, et al. Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care 20 November 2025; 48 (12): 2012–2020. https://doi.org/10.2337/dc24-2841 DeFronzo et al. Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment. Diabetes Care 20 November 2025; 48 (12): 2036–2044. https://doi.org/10.2337/dc25-1055 MOMENTUM: Hypercortisolism Present in 1-in-4 with Resistant Hypertension. HCP Live, March 2026
With over 200,000 hospital admissions each year from diabetic ketoacidosis, new continuous ketone monitoring systems can address a critical care gap. In the second part of our special series, Neil Skolnik explores the value of this new technology and delves into specific case studies. This special episode is sponsored with support from Abbott. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Heath Sciences, Boston, Mass.; Clinical pharmacist and the Clinical Director of Cardiometabolic Services at Well Life Medical in Peabody, MA References: Hyperglycemic Crises in Adults With Diabetes: A Consensus Report. Diabetes Care 2024;47:1257–1275 doi.org/10.2337/dci24-0032 Continuous ketone monitoring: Exciting implications for clinical practice. Diabetes Obesity, and Metabolism. 2024; 26 (Suppl. 7): 47-58. doi.org/10.1111/dom.15921 Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology. The Lancet Diabetes & Endocrinology. 2026; 14:82 doi.org/10.1016/S2213-8587(25)00331-6
There are multiple options now for slowing the progression of chronic kidney disease. In part 5 of our special series, host Dr. Neil Skolnik takes a case-based approach to explore treatment options for CKD. This special episode is sponsored with support from Bayer. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Holly Kramer, MD, MPH, Professor of Public Health Sciences and Medicine in the Division of Nephrology and Hypertension at Loyola University in Chicago, Illinois Selected References: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 doi.org/10.2337/dc26-S011 Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 doi.org/10.1056/NEJMoa2025845 Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 doi.org/10.1056/NEJMoa2024816 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121 doi.org/10.1056/NEJMoa2403347 Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care 2023;46(9):1574–1586 doi.org/10.2337/dci23-0030 The Kidney Failure Risk Equation - kidneyfailurerisk.com
Welcome to the latest episode (November 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Oser, et al. Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes. New England Journal of Medicine. October 2026; doi.org/10.1056/NEJMoa2608571 Islet autoantibody screening identifies early-stage type 1 diabetes across Europe, Need-To-Know Institute press release Yang, et al. Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis. JAMA. Published online October 2026. doi.org/10.1001/jama.2026.19921 Jastreboff, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. September, 2026. doi.org/10.1056/NEJMoa2604169 Bellido, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. Volume 408, Issue 10563. doi.org/10.1016/S0140-6736(26)01861-1 Colhoun, et al. Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial. European Heart Journal. 2026; ehag524, doi.org/10.1093/eurheartj/ehag524 Garvey, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Diabetes & Endocrinology, 2026; 14, 914-926. doi.org/10.1016/S2213-8587(26)00213-5 Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's three science and medical journals—Diabetes, Diabetes Care, and Diabetes, Obesity, and CardioMetabolic CARE. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research is relevant in clinical practice. For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here.
We are entering an era of choice in terms of diabetes and obesity therapies. Choice is good, but having a keen understanding of each medication is crucial to avoid being overwhelmed. In this special episode of DOC Updates, host Dr. Neil Skolnik explores the latest amylin-based therapies. This special episode is sponsored with support from Novo Nordisk. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Juan Pablo Frias, MD, Medical Director and Principal Investigator, Los Angeles Institute for Metabolic Research, Adjunct Professor of Medicine at Charles Drew University of Medicine and Science Selected References: Garvey, et al. "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity," N Engl J Med 2025;393:635-647 doi.org/10.1056/NEJMoa2502081 Aroda V, Buzzetti R, Dalskov S et al. "Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study," The Lancet Diabetes & Endocrinology, 2026; 14, 649-661 doi.org/10.1016/S2213-8587(26)00126-9






